Edap Tms (EDAP) Lowered to Sell at Zacks Investment Research

Edap Tms (NASDAQ:EDAP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

A number of other brokerages have also recently commented on EDAP. HC Wainwright set a $7.00 price objective on shares of Edap Tms and gave the stock a “buy” rating in a research note on Friday, May 17th. TheStreet raised shares of Edap Tms from a “c” rating to a “b-” rating in a research note on Wednesday, May 8th. Finally, ValuEngine cut shares of Edap Tms from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th.

Shares of EDAP stock traded down $0.01 on Wednesday, hitting $3.45. 80,839 shares of the stock traded hands, compared to its average volume of 199,276. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.40 and a quick ratio of 1.97. The company has a market capitalization of $100.04 million, a price-to-earnings ratio of 172.50 and a beta of 1.90. Edap Tms has a 52 week low of $1.35 and a 52 week high of $5.42.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings results on Wednesday, May 15th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.01. The company had revenue of $11.50 million for the quarter, compared to the consensus estimate of $13.25 million. Edap Tms had a negative net margin of 0.36% and a negative return on equity of 1.13%. Equities research analysts expect that Edap Tms will post 0.11 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of EDAP. Naples Global Advisors LLC purchased a new position in shares of Edap Tms in the 4th quarter worth $31,000. Commonwealth Equity Services LLC grew its stake in shares of Edap Tms by 27.0% in the 1st quarter. Commonwealth Equity Services LLC now owns 23,500 shares of the medical equipment provider’s stock worth $70,000 after buying an additional 5,000 shares in the last quarter. Hilton Capital Management LLC purchased a new position in shares of Edap Tms in the 1st quarter worth $75,000. Finally, Fosun International Ltd grew its stake in shares of Edap Tms by 46.0% in the 4th quarter. Fosun International Ltd now owns 249,143 shares of the medical equipment provider’s stock worth $421,000 after buying an additional 78,516 shares in the last quarter. 10.07% of the stock is owned by institutional investors and hedge funds.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Article: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.